Android app Apple app link

Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe

By Yahoo! Finance   |   1 month ago
Teva Pharmaceutical (TEVA) Enters Into a License Agreement With Prestige Biopharma for the Commercialization of Tuznue in Europe

Teva Pharmaceutical Industries Limited offers an affordable stock option under $20 with a recent licensing agreement for the commercialization of Tuznue, a biosimilar to Herceptin in European markets.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.